Because of the risk of confusion, hypomania, hallucination and manic episodes, agitation, myoclonus, hyperreflexia, incoordination, shivering, tremor, convulsion, ataxia, diaphoresis, diarrhea, fever, hypertension, which can be part of the serotonine syndrome, concomitant administration of selegiline and ssris or snris is contraindicated. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Interaction with other medicinal products and other forms of interaction because of the risk of hypertension, co-administration of selegiline and sympathomimetics is contraindicated.
Parkinsons disease patients treated with dopamine agonists and other dopaminergic treatments have been reported as exhibiting impulse control disorders and compulsions like pathological gambling, increased libido, hypersexuality, binge eating, shopping and different kinds of compulsiverepetitive activities (punding). Caution should be exercised in patients receiving mao inhibitors during general anaesthesia in surgery. Physico-chemical data on selegiline point to excretion in breast milk and a risk to the suckling child cannot be excluded.
Caution is advised when selegiline is taken in combination with other centrally acting medicinal products and substances. Studies have related the risk of an increased hypotensive response to concomitant administration of selegiline and levodopa, in patients with cardiovascular risk. When selegiline is added to a levodopa regimen it is possible to reduce the levodopa dosage by an average of 10 -30.
Mao inhibitors, including selegiline, may potentiate the effects of cns depressants used for general anaesthesia. Similar experience has been reported in patients receiving selegiline and two other serotonin reuptake inhibitors, sertraline and paroxetine. In general, selegiline should not be introduced after a drug that is known to interact with selegiline, until after 5 half lives of that drug have elapsed.
Patients being treated with selegiline currently or within the past 2 weeks should receive dopamine only after careful risk-benefit assessment, as this combination enhances the risk of hypertensive reactions. Concomitant use of hypertensive agents, antihypertensives, psychostimulants, central suppressant drugs (sedatives, hypnotics) and alcohol should be avoided. When prescribing this medicine, patients should be told however, you would not be committing offence (called statutory defence) if o the medicine has been prescribed to treat a medical or dental problem and o you have taken it according to the instructions given by the prescriber and in the information provided with the medicine and the following undesirable effects have been reported with selegiline during clinical trials andor post-marketing use.
This class of medicine is in the list of drugs included in regulations under 5a of the road traffic act 1988. When suggestions are available use up and down arrows to review and enter to select. When selegiline is added to the maximum tolerated dose of levodopa, involuntary movements and agitation may occur. Concomitant administration of amantadine and anticholinergic drugs can lead to an increased occurrence of side-effects. When an optimum dose of levodopa is reached, adverse effects from the combination are less than those observed with levodopa on its own.
Transient or continuing abnormalities with a tendency for elevated plasma concentrations of liver enzymes have been described during long-term therapy with conventional tablets of selegiline. Valid at all major chains including walgreens, cvs pharmacy, target, walmart pharmacy, duane reade and 65,000 pharmacies nationwide. Discount card works like a coupon and can save you up to 80 or more off the cost of prescription medicines, over-the-counter drugs and pet prescriptions. Selegiline in combination with maximal levodopa therapy is indicated particularly in patients who experience fluctuations in their condition such as end-dose type fluctuations, on-off symptoms or other dyskinesias. Eldepryl is contra-indicated in patients with known hypersensitivity (including severe dizziness or hypotension) to selegiline or any of the excipients listed in section 6.
The combined use of the ssri, fluoxetine and eldepryl, should only be used under clinical supervision. For all other serotonin reuptake inhibitors, a time interval of 1 week is recommended between discontinuation of the serotonin reuptake inhibitor and initiation of selegiline. Data sources include micromedex (updated aug 2nd, 2018), cerner multum (updated aug 6th, 2018), wolters kluwer (updated aug 3rd, 2018) and others. Selegiline should not be used in patients who are being treated with antidepressant drugs, including mao inhibitors, tricyclic antidepressants, serotonin noradrenaline reuptake inhibitors (snri) (venlafaxine) and selective serotonin reuptake inhibitors (e. However, due to stock shortages and other unknown variables we cannot provide any guarantee.
Special care should be taken when administering selegiline to patients who have labile hypertension, cardiac arrhythmias, severe angina pectoris, psychosis or a history of peptic ulceration as aggravation of these conditions may occur during treatment. Interaction with other medicinal products and other forms of interaction because of the risk of hypertension, co-administration of selegiline and sympathomimetics is contraindicated. Studies in animals have shown reproductive toxicity only at high multiple of human doses. Selegiline should not be started until 2 weeks after stopping sertraline. Since selegiline potentiates the effects of levodopa, the adverse effects of levodopa may be increased. Concomitant administration of selegiline and mao inhibitors may cause central nervous and cardiovascular system disorders (see section 4. Since fluoxetine has a very long elimination half life, at least 5 weeks should be allowed after stopping fluoxetine and before starting selegiline. Mao inhibitors, including selegiline, may potentiate the effects of cns depressants used for general anaesthesia. Eldepryl (selegiline) is a member of the dopaminergic antiparkinsonism agents drug class and is commonly used for parkinsons disease. Selegiline should not be used in patients with other extrapyramidal disorders not related to dopamine deficiency.Eldepryl 5 mg Tablets. Eldepryl 10 mg Tablets. (Selegiline hydrochloride). Read all of this leaflet carefully before you start taking this medicine because it ...